SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
CHL is strengthening its play in the fast-growing beauty and personal care sector
The demand in Africa for COVID-19 vaccines has declined
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Fluid bed processes: drying, granulating, and coating in just one product container
A game changing solution for the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
